Fractyl Health (GUTS) Set to Announce Quarterly Earnings on Wednesday

Fractyl Health (NASDAQ:GUTS) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Fractyl Health to post earnings of ($1.59) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.18. On average, analysts expect Fractyl Health to post ($5.88) EPS for the current fiscal year and ($4.87) EPS for the next fiscal year.

Fractyl Health Trading Up 4.7%

NASDAQ:GUTS traded up $0.04 during mid-day trading on Wednesday, hitting $0.94. 63,620 shares of the company’s stock were exchanged, compared to its average volume of 340,893. The company has a 50 day simple moving average of $5.13 and a 200-day simple moving average of $7.80. Fractyl Health has a fifty-two week low of $0.82 and a fifty-two week high of $29.34. The firm has a market capitalization of $12.46 million, a P/E ratio of -0.09 and a beta of 2.91. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wall Street Zen lowered Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Craig Hallum set a $5.00 price target on Fractyl Health in a report on Monday, October 19th. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Finally, Morgan Stanley decreased their price objective on shares of Fractyl Health to $4.00 and set an “equal weight” rating for the company in a research report on Monday, October 19th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Fractyl Health has an average rating of “Hold” and an average target price of $50.25.

About Fractyl Health

Fractyl Health, Inc is a biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company aims to create treatments that address the underlying biology of these conditions and provide longer-lasting alternatives to frequently administered medicines.

Fractyl Health’s technology platforms include Revita, an endoscopic procedure designed to modify the lining of the duodenum and potentially improve metabolic function, and a gene therapy platform intended to enable the body to produce therapeutic levels of metabolic hormones such as glucagon-like peptide-1 (GLP-1).